Generex Biotechnology Corporation 

(Public, NASDAQ:GNBT)   Watch this stock   
Find more results for GNBT
Oct 14, 2009
Q4 2009 Earnings Release
Sep 10, 2009
Rodman & Renshaw Annual Global Investment Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Jul '09) 2009
Net profit margin -10619.80% -4094.01%
Operating margin -6769.31% -2346.38%
EBITD margin - -2284.81%
Return on average assets -205.18% -145.52%
Return on average equity -521.79% -248.49%
Employees 43 -

Address

33 Harbour Square Suite 202
Toronto, ON M5J 2G2
Canada
+1-416-3642551 (Phone)
+1-416-3649363 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Generex Biotechnology Corporation discussed on blogs

VFC's STOCK HOUSE: Readers Respond: FCSC, PWRM, NEPH, GNBT - vfcshouse@hotmail.com (VFC) - VFC's STOCK HOUSE - 5 hours ago
Our Stock Picks for today (www.hypergrowthstock.com) | Kazor World ... - hypergrowthstock - Kazor World Community News - 5 hours ago

Generex Biotechnology Corporation discussions

  View all discussions »

Description

Generex Biotechnology Corporation (Generex) is a development-stage company. The Company is engaged in the research, development and commercialization of drug delivery systems and technologies. The Company is focused on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Through its wholly owned subsidiary, Antigen Express, Inc. (Antigen), the Company has expanded its focus to include immunomedicines incorporating vaccine formulations. The Company’s subsidiaries include Generex Pharmaceuticals Inc., Generex (Bermuda), Inc., Generex Pharmaceuticals (USA) LLC and Generex Marketing & Distribution Inc. In April 1999, the Company completed a reorganization in which it merged with Generex Idaho. In September 2009, the Company announced the incorporation of SIA Generex Biotechnology BALTIC as a wholly owned subsidiary.

Officers and directors

Anna E. Gluskin
Chairperson of the Board, President, Chief Executive Officer
Age: 58
Bio & Compensation - Reuters
Rose C. Perri
Chief Financial Officer, Chief Operating Officer, Treasurer, Secretary, Director
Age: 42
Bio & Compensation - Reuters
Mark Fletcher
Executive Vice President, General Counsel
Age: 43
Bio & Compensation - Reuters
Gerald Bernstein M.D.
Vice President - Medical Affairs
Age: 76
Bio & Compensation - Reuters
John P. Barratt
Independent Director
Age: 65
Bio & Compensation - Reuters
Brian T. McGee
Independent Director
Age: 48
Bio & Compensation - Reuters
Nola E. Masterson
Independent Director
Age: 62
Bio & Compensation - Reuters